Compounded medicine, mucoadhesive buccal films of semaglutide 2mg (double the 1mg maintenance dose) made by APC Labs for adults needing more active GLP-1 support than maintenance dosing provides
Same needle-free buccal delivery format as SLIM Films 1mg, but with double the semaglutide content per film. Delivered through the inner cheek via mucoadhesive Novafilm base with menthol permeation enhancer
Higher-intensity positioning between maintenance and active weight loss dosing. Fits patients transitioning from higher-dose injections, those whose 1mg dose isn’t providing enough effect, and those needing stronger food noise reduction
Semaglutide contraindications still apply: medullary thyroid cancer, MEN2, previous pancreatitis, pregnancy. GI side effects may be more prominent at 2mg than 1mg. Prescriber assessment before supply is essential
You’ve come off the higher-dose injections, or you’re planning to. Perhaps you were on Wegovy 2.4mg weekly. Perhaps you were on Mounjaro at one of the higher doses. Either way, your body has been getting significant GLP-1 support. So stepping straight down to maintenance-level dosing feels like too big a drop.
Or perhaps you started with SLIM Films 1mg and found the effect wasn’t quite enough. The food noise crept back. Portion sizes started creeping up. The appetite regulation you needed just wasn’t there.
This isn’t a failure of the maintenance approach. Different patients simply need different levels of ongoing GLP-1 support. After all, weight regulation is genuinely multifactorial. Hormones, metabolism, stress, sleep, and individual biology all play a part. As a result, the right level of support changes at different stages.
What the 2mg strength offers
SLIM Films 2mg fit the space between maintenance and active weight loss dosing. Each film delivers double the semaglutide of the 1mg strength. The buccal delivery format stays the same. So the aim is more active appetite regulation for patients who need it.
This suits three groups. First, those transitioning from higher-dose injections who want stronger ongoing support. Second, those whose 1mg dose isn’t doing enough. Third, those whose food noise or portion control needs firmer management.
The honest limits of 2mg dosing
However, we want to be straight about what SLIM Films 2mg are and are not.
They aren’t equivalent to a full 2.4mg weekly Wegovy injection for driving new weight loss. So if you’re still working towards a weight goal, injection therapy fits better. Nor do they guarantee outcomes, because weight management is genuinely multifactorial.
They’re also an unlicensed compounded medicine. As a result, the evidence base for buccal semaglutide at this strength is smaller than for licensed injectables. Side effects may be more prominent at 2mg than at 1mg, particularly nausea and other gastrointestinal effects.
In short, they work best as one part of a comprehensive approach. Your prescriber helps decide whether that fits your situation.
This is a compounded medicine — mucoadhesive buccal films containing semaglutide 2mg (a GLP-1 receptor agonist), designed to be placed against the inner cheek and left to dissolve. So each film delivers a higher dose of semaglutide directly through the buccal mucosa, bypassing the digestive system entirely.
As a result, SLIM Films 2mg offer a stronger buccal GLP-1 option than the 1mg maintenance strength, fitting adults who need more active appetite regulation than maintenance dosing provides. This includes patients transitioning off higher-dose GLP-1 injections who want stronger ongoing support, patients whose 1mg SLIM Films aren’t providing enough effect, or patients who need higher-intensity food noise reduction than 1mg dosing delivers.
Important: this is an unlicensed compounded medicine, and semaglutide has genuine cardiovascular, pancreatitis, and thyroid contraindications. So prescriber assessment is essential before supply. Available at Medical Mojo after full clinical review.
At Medical Mojo, we believe in treatment that fits the person, but only where it’s honest, safe, and consented to.
This page covers what SLIM Films 2mg are, how the higher-strength positioning differs from 1mg maintenance dosing, who they may suit, how they compare to injections and other buccal options, and the practical points that matter — including realistic clinical positioning, appropriate use, and when injection continuation or 1mg maintenance dosing might suit better.
Regulatory position — please read first
Before going further, we want to be straight with you about four things:
First, SLIM Films 2mg are an unlicensed compounded medicine manufactured to prescriber order under GPhC-regulated compounding standards by our compounding partner APC Labs Ltd (GPhC 9012301, Southampton). So they aren’t licensed medicines like Wegovy, Ozempic, or Rybelsus. Instead, they’re compounded medicines made available under the compounding pathway where a prescriber judges an alternative formulation is needed to meet a specific clinical need.
Second, the 2mg strength is deliberately higher than the 1mg maintenance dose. So it’s positioned for patients who need more active GLP-1 receptor engagement than pure maintenance dosing provides. This includes patients transitioning from higher-dose injection therapy, patients whose 1mg dose isn’t providing enough effect, and patients needing stronger ongoing appetite regulation. It isn’t a replacement for full weight-loss dose injections in patients still actively losing weight.
Third, semaglutide has important safety considerations. Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, severe gastrointestinal disease, and pregnancy are all reasons semaglutide can’t be used. So our prescriber assesses these before first supply, and side effects (particularly gastrointestinal) may be more prominent at the higher dose.
Fourth, the evidence base for buccal semaglutide specifically is limited. While the semaglutide molecule itself has extensive evidence (STEP trials, SUSTAIN trials, SELECT trial for cardiovascular outcomes), the buccal delivery format has less specific clinical trial data compared to subcutaneous injection or oral tablet formulations. As a result, our prescriber discusses what this means for realistic expectations, dose response variability, and monitoring approach before supply.
If any of these points raise concerns, please talk to our prescriber before proceeding. After all, higher-strength GLP-1 therapy needs proper clinical judgement, not just prescription fulfilment.
Five key takeaways
SLIM Films 2mg are a compounded medicine — mucoadhesive buccal films of semaglutide 2mg made by GPhC-regulated compounding partner APC Labs to individual prescriber order. The higher-strength option in the SLIM Films range, positioned above the 1mg maintenance dose
Same buccal delivery format as SLIM Films 1mg. Films adhere to the inner cheek, dissolve over minutes, and deliver semaglutide through the buccal mucosa into systemic circulation, bypassing gastric degradation entirely. Uses the same Novafilm base with menthol as a permeation enhancer
Higher-intensity positioning — typical use is one to two films per week, providing stronger GLP-1 receptor engagement than 1mg maintenance dosing. Aimed at patients who need more active appetite regulation than pure maintenance dosing provides, or those transitioning from higher-dose injection therapy
Same practical advantages as 1mg SLIM Films — needle-free option, no cold chain required, discreet and portable, no injection technique needed. Films dissolve in the mouth without water. Suitable for vegetarians (Novafilm base contains no animal-derived ingredients)
Side effects (particularly nausea and gastrointestinal) may be more prominent at 2mg than at 1mg. Semaglutide contraindications still apply — medullary thyroid carcinoma, MEN2 syndrome, previous pancreatitis, pregnancy, breastfeeding all rule out use. Prescriber assessment before supply is essential, not optional
Key features and specs
Active ingredient: semaglutide 2mg per film
Class: GLP-1 receptor agonist
Form: mucoadhesive buccal film
Base: Novafilm (vegetarian-suitable)
Permeation enhancer: menthol
Route: buccal (against inner cheek)
Dissolution time: typically minutes
Frequency: once or twice weekly (as prescribed)
Positioning: higher-intensity ongoing GLP-1 support, between maintenance and active weight loss dosing
Legal status: unlicensed compounded medicine
Manufacturer: APC Labs Ltd (GPhC 9012301), Southampton, to Medical Mojo prescriber order
Storage: room temperature, in original packaging
Shelf life: as determined by stability data on supply
Not for: active weight loss phase, pregnancy, breastfeeding, medullary thyroid cancer, MEN2, previous pancreatitis
Pack details
SLIM Films 2mg come as:
Individual single-dose films
Typically supplied in packs matching prescribed frequency (4 or 8 film packs)
Each film is single-use
Sealed until use
Clearly distinguished from 1mg SLIM Films by packaging to prevent dose confusion
How they’re made
Important transparency points:
Compounded to prescriber order at APC Labs Ltd (GPhC 9012301)
Made under GPhC compounding manufacturing standards
Semaglutide sourced from approved API supplier
Quality control includes content uniformity, dissolution, and microbial testing
Room temperature storage suitable
Shelf life determined by stability data
Batch documentation retained per compounding manufacturing standards
After all, this is compounded rather than industrially manufactured. So the regulatory pathway is genuinely different from licensed products like Wegovy or Ozempic, and being clear about that matters.
Why choose Medical Mojo for higher-intensity GLP-1 support
At Medical Mojo, our approach starts with a simple idea: treatment should fit the person, not force the person to fit the system.
Dr Rosalind Jex
Our service is shaped by the philosophy of Dr Rosalind Jex, our brand pharmacist.
Dr Rosalind represents the spirit of the pharmacy: evidence-led, community-rooted, and willing to challenge the one-size-fits-all approach to medicine. She is named in honour of two pioneering women in science: Rosalind Franklin, the chemist and X-ray crystallographer whose work revealed the structure of DNA; and Sophia Jex-Blake, the first female doctor in the UK, who fought the medical establishment for the right to practise.
In her steampunk laboratory, Dr Rosalind works against pharma’s standardised approach to medicine. In the real world, she represents what we stand for. Her view is straightforward: you are not broken. The system is. And we are here to change that.
Higher-intensity support deserves proper consideration
Not every patient’s maintenance needs are the same. Medical Mojo is different. So we recognise that:
Different patients need different levels of ongoing GLP-1 support
Standard ‘one dose fits all’ maintenance approaches don’t suit everyone
Patients coming off higher-dose injections may need more than maintenance-level ongoing support
Food noise return can be genuinely disruptive even after successful weight loss
Getting the right level of ongoing support matters for long-term outcomes
Prescriber judgement about strength matters
Honest framing about 2mg vs 1mg
Stronger isn’t automatically better:
2mg provides more active appetite regulation than 1mg
2mg has higher rates of gastrointestinal side effects
Some patients tolerate 2mg well and benefit from stronger effect
Others find 2mg too much and do better on 1mg
Individual factors determine best strength
Starting on 1mg and stepping up if needed is often sensible
Sometimes stepping down from 2mg to 1mg is the right move
Honest framing about 2mg vs injection continuation
Different pharmacokinetics matter:
2mg buccal semaglutide provides more active support than 1mg maintenance
However, it isn’t equivalent to 2.4mg weekly Wegovy injection
Injection continuation has stronger evidence base
Injection continuation provides more consistent plasma concentrations
2mg SLIM Films fit needle-free preference at active-intensity dose
If you’re still actively losing weight, continued injection therapy usually fits better
Honest framing about GLP-1 discontinuation and weight regain
The data:
STEP 1 extension trial: patients regained approximately two-thirds of weight lost within a year of stopping
SURMOUNT-4: similar pattern for tirzepatide
This isn’t a treatment failure, it reflects the chronic nature of obesity biology
Obesity is now understood as a chronic condition needing ongoing management
Many patients need long-term or intermittent pharmacological support
Higher-intensity support may fit patients transitioning from high injection doses
Individual factors matter significantly
Honest framing about the compounded medicine status
What this means:
SLIM Films are unlicensed compounded medicines — not licensed medicines like Wegovy or Ozempic
Made under GPhC-regulated compounding manufacturing standards
Individual prescriber judgement basis for supply
Less specific evidence base than licensed products
MHRA regulates unlicensed compounded medicines differently from licensed products
The compounding pathway exists precisely because alternative formulations meet specific clinical needs
However, licensed products preferred where they meet the need
Higher-intensity support and the bigger picture
Weight management rarely sits in isolation. So our prescriber can discuss:
Comprehensive approach
Dietary patterns that sustain outcomes
Physical activity for weight management
Sleep quality and weight regulation
Stress and emotional eating
Menstrual cycle and hormonal factors
Menopause and weight regulation
Cardiovascular risk maintenance benefits
Metabolic markers monitoring
When to consider dose adjustment (up or down)
When to transition off pharmacological support
When to consider return to injection therapy
Sometimes weight maintenance is one part of a wider health picture worth talking through.
Prescriber support before and after supply
Our team is here to discuss:
Whether SLIM Films 2mg fit your specific situation
Whether 1mg would suit you first
Alternative approaches
Comprehensive lifestyle work alongside pharmacological support
Correct application technique
Realistic expectations at 2mg vs 1mg
Monitoring approach
What to do if you don’t feel enough effect
What to do if side effects are troublesome
When to review or adjust strength
Trust earned, not claimed
We are GPhC-regulated, and our content is grounded in the licensed Wegovy, Ozempic, and Rybelsus Summary of Product Characteristics documents (Novo Nordisk) for the semaglutide molecule characteristics, STEP trial evidence base for semaglutide efficacy in weight management, STEP 1 extension trial for post-cessation weight regain data, SELECT trial for cardiovascular outcomes, SURMOUNT trials for tirzepatide comparison data, MHRA guidance on unlicensed compounded medicine manufacturing, GPhC standards for pharmacy compounding, and the real experience of patients managing weight after GLP-1 injection therapy.
If SLIM Films 2mg aren’t the right answer for your situation, we’ll tell you honestly. After all, getting the right approach matters more than fulfilling a request.
How supply works
This is a compounded medicine. So the supply process has proper clinical steps.
How our service works
Complete the detailed weight management consultation on medicalmojo.co.uk
Our UK-qualified prescriber reviews your weight management history and current situation
The prescriber assesses whether 2mg is appropriate vs 1mg or other approaches
If approved, the prescriber issues a compounding order
APC Labs compounds your specific supply under GPhC-regulated compounding manufacturing
Your order is dispatched in plain, discreet packaging
Free prescriber support is available throughout treatment
Regular review to assess response and consider dose adjustments
When other options might suit better
If SLIM Films 2mg aren’t right, we’ll explain why. Other options may include:
SLIM Films 1mg — for pure maintenance dosing
Continued Wegovy injections at maintenance dose
Continued Ozempic injections (for diabetic patients)
Continued Mounjaro injections at maintenance dose
Reduced-dose weekly injections
Extended interval injection (every 2 weeks or monthly)
Rybelsus oral tablets
THIN sublingual sprays (Medical Mojo alternative buccal option)
Specialist obesity medicine referral for complex cases
Bariatric surgery consideration for eligible patients not maintaining
What the consultation covers
This is a compounded medicine. So supply only happens after our UK-qualified prescriber reviews your situation thoroughly. The consultation covers:
Your weight management history
Details of GLP-1 injection therapy already completed
Duration and doses of previous injection therapy
Weight lost during injection therapy
Time since stopping injections and current weight trajectory
Whether SLIM Films 1mg have been tried and found insufficient
Return of food noise or appetite dysregulation
Personal and family history of medullary thyroid cancer or MEN2
History of pancreatitis
Gallbladder history
Any relevant medical history
Current medications
Pregnancy status if applicable
Understanding of the compounded status
Realistic expectations for higher-intensity vs full weight-loss dosing
Tolerance considerations at the 2mg dose
Ongoing lifestyle work
Monitoring plan
In short, this isn’t a checkbox consultation. It’s a clinical assessment about the right approach for your specific situation. So we take time to make sure the 2mg strength genuinely fits your needs rather than just stronger being assumed to be better.
Active ingredients
Each SLIM Film contains:
Semaglutide 2mg (GLP-1 receptor agonist)
Menthol (permeation enhancer)
Novafilm base (mucoadhesive film-forming excipient, suitable for vegetarians)
Why semaglutide
Semaglutide is one of the most extensively studied GLP-1 receptor agonists:
Human GLP-1 analogue (94% amino acid sequence similarity)
Long half-life (approximately 165 hours or around 7 days)
Allows weekly rather than daily dosing
GLP-1 receptor agonist with effects on appetite regulation, gastric emptying, and glucose metabolism
Licensed as Ozempic for type 2 diabetes and Wegovy for weight management
Also licensed as Rybelsus (oral tablet form)
STEP trials (STEP 1-8) demonstrated efficacy in weight management
SUSTAIN trials demonstrated glycaemic control efficacy
SELECT trial demonstrated cardiovascular outcome benefits in overweight patients with established cardiovascular disease
Well-characterised safety profile from extensive post-marketing surveillance
In short, semaglutide is one of the reference GLP-1 receptor agonists with a strong evidence base.
Why the 2mg strength
The 2mg dose is deliberately higher than the 1mg maintenance strength:
Double the 1mg maintenance dose in the same film format
Positioned around the 2.4mg weekly injectable dose used for active weight management with Wegovy in terms of nominal milligrams, but delivered by a route with lower and more variable bioavailability, so the delivered exposure is expected to be lower
Above the standard Ozempic maintenance dosing for diabetes (0.5-1mg weekly)
Positioned between maintenance and active weight loss dosing in terms of expected clinical effect
Accounts for the likely variability in buccal absorption compared to subcutaneous injection
Allows once or twice weekly dosing based on individual response
Provides stronger background GLP-1 receptor activity than 1mg
Balances stronger effect with tolerability considerations
After all, the 2mg strength gives an intermediate option between pure maintenance and full active weight loss dosing. So the strength reflects the specific clinical scenarios it targets, providing more active support without matching the intensity of full weight-loss injection doses.
Why the buccal film format
The buccal route offers the same specific practical advantages as the 1mg version:
Needle-free — no injection technique required
No cold chain — films stable at room temperature
Portable — fits in a pocket or handbag
Discreet — usable in most settings without attracting attention
Bypasses gastric acid and digestive enzymes that would degrade semaglutide
Avoids first-pass hepatic metabolism
Mucoadhesive coating allows prolonged contact with buccal mucosa for absorption
Rapid dissolve — films typically dissolve within minutes
No swallowing required — suitable for patients with dysphagia
Doesn't require water or food
In short, the buccal route addresses the same practical barriers as 1mg SLIM Films, but delivers a higher dose for patients needing stronger effect. So for patients whose 1mg dose isn't enough, the 2mg option provides more active support while keeping the practical advantages of the buccal format.
Why menthol as permeation enhancer
Menthol serves the same specific pharmaceutical function as in the 1mg version:
Enhances permeability of the buccal mucosa
Increases absorption of the semaglutide through the buccal tissue
Well-established as a permeation enhancer in oral and mucosal drug delivery
Provides mild pleasant taste
Provides mild sensory feedback confirming film placement
Recognised as safe in this application
Why Novafilm base
Novafilm is a proprietary mucoadhesive film-forming platform:
Adheres to the buccal mucosa on contact
Prevents film displacement during dissolution
Provides sustained release of active over the dissolution period
Suitable for vegetarians (contains no animal-derived ingredients, derived from sea weed)
Well-tolerated on the buccal mucosa
Dissolves cleanly without residue
Compatible with menthol permeation enhancement
Other ingredients
Additional excipients in the Novafilm base support film integrity, adhesion, and controlled dissolution.
Complete excipients list is provided with each supply. So mention any known allergies or sensitivities during your consultation.
What are SLIM Films 2mg for?
SLIM Films 2mg are designed for adults who need higher-intensity GLP-1 receptor engagement than the 1mg maintenance strength provides. So the target scenarios include patients transitioning from higher-dose GLP-1 injection therapy who need meaningful ongoing support, patients whose 1mg dose isn't providing enough effect, and patients whose food noise or appetite dysregulation needs stronger management. As a result, they fit specific transition points in the weight management journey where 1mg maintenance dosing isn't quite enough.
Who might SLIM Films 2mg suit?
This product may suit:
Adults transitioning off higher-dose GLP-1 injection therapy (Wegovy 2.4mg, Mounjaro high doses)
Adults who tried SLIM Films 1mg and found the effect insufficient
Adults with significant food noise return after stopping injections
Adults who need more active appetite regulation than pure maintenance dosing
Adults wanting stronger ongoing GLP-1 support without returning to injections
Adults with needle phobia needing more than maintenance-level GLP-1 activity
Adults with hormonal weight regain patterns needing stronger support
Adults committed to lifestyle changes alongside pharmacological support
Adults without contraindicating conditions
Adults tolerating GLP-1 gastrointestinal effects (nausea may be more prominent at 2mg)
Adults understanding this is an unlicensed compounded medicine
Adults engaged with prescriber-led review and monitoring
What SLIM Films 2mg may help with
Based on the pharmacology of semaglutide and the higher-dose positioning:
Stronger appetite regulation than 1mg dosing provides
More significant food noise reduction
Snack prevention through stronger satiety signalling
Meaningful support during transition off higher-dose injection therapy
Support for patients whose weight is drifting despite 1mg maintenance
Reduced portion sizes at meals through earlier and stronger satiety
Higher-intensity support during vulnerable periods (major life transitions, stress, hormonal changes)
Ongoing needle-free GLP-1 receptor engagement at active-intensity dose
Important honesty point: 2mg dosing sits between maintenance and full active weight loss dosing. So while it provides stronger support than 1mg, it isn't equivalent to full 2.4mg weekly Wegovy injections for driving new weight loss. After all, buccal absorption is less consistent than subcutaneous injection, and the clinical trial evidence base for buccal delivery specifically remains limited compared to injectable formulations.
What SLIM Films 2mg don't claim to do
Honest framing matters:
They don't provide the active weight loss effect of full-dose 2.4mg weekly injections
They don't guarantee weight loss or prevention of weight regain
They don't replace the need for dietary changes and physical activity
They don't address underlying causes of weight gain
They don't work overnight — steady state builds over weeks
They don't treat diabetes as a licensed indication
They don't work in medullary thyroid cancer or MEN2 syndrome — contraindicated
They don't have the extensive clinical trial evidence of licensed GLP-1 formulations
They aren't automatically better than 1mg — higher dose means more side effect risk too
Stage 2: Active weight loss — full-dose weekly injectable GLP-1 (semaglutide 2.4mg weekly as Wegovy, or tirzepatide up to 15mg weekly as Mounjaro)
Stage 3: Weight loss consolidation — continued injections at maintenance doses
Stage 4: Transition to maintenance — reducing injection dose or switching to alternative approaches
Stage 5: Active maintenance phase — higher-intensity ongoing GLP-1 support (SLIM Films 2mg fit here) for patients needing more than pure maintenance
Stage 6: Standard maintenance phase — lower-intensity ongoing GLP-1 support (SLIM Films 1mg fit here) plus continued lifestyle work
Stage 7: Gradual reduction — some patients may reduce or stop maintenance therapy as lifestyle becomes established
Stage 8: Long-term monitoring — ongoing review, weight tracking, and pharmacological support if needed
Stage 9: Re-treatment cycles if needed — many patients need multiple treatment cycles across their lifetime
So SLIM Films 2mg sit at Stage 5, providing more active support than pure maintenance dosing but less intensity than full-dose active weight loss injections. In short, they fill the gap for patients who need meaningful ongoing GLP-1 support without returning to injections.
SLIM Films 2mg vs SLIM Films 1mg
Different strengths for different scenarios:
SLIM Films 2mg: higher-intensity, more active appetite regulation
In contrast, SLIM Films 1mg: pure maintenance dosing after injection therapy
Both use identical delivery format (buccal, Novafilm base, menthol)
Both dosed once or twice weekly
2mg provides stronger effect, particularly for food noise reduction
2mg has higher rates of gastrointestinal side effects
1mg fits patients wanting minimal ongoing support
2mg fits patients transitioning from higher-dose injections or needing more effect
Some patients start on 2mg then step down to 1mg over time
Others start on 1mg and step up to 2mg if response is insufficient
In general, prescriber discussion determines which fits your situation
SLIM Films 2mg vs continuing weekly Wegovy 2.4mg
Higher-intensity buccal vs full-dose injection:
SLIM Films 2mg: buccal delivery, 2mg once or twice weekly
In contrast, Wegovy 2.4mg: subcutaneous injection weekly
Wegovy has extensive STEP trial evidence for active weight loss
Wegovy delivers higher, more consistent plasma concentrations
Wegovy is a licensed product with regulatory approval for weight management
SLIM Films 2mg are unlicensed compounded medicines
If you're still actively losing weight, Wegovy injections fit better
If you've reached your goal weight and want lower-intensity ongoing support, SLIM Films fit
SLIM Films 2mg needle-free vs weekly Wegovy injections
In general, injection continuation at maintenance dose is more evidence-based; SLIM Films 2mg fit needle avoidance preference
SLIM Films 2mg vs continuing weekly Mounjaro
Different actives and delivery:
SLIM Films 2mg: buccal semaglutide, weekly to twice-weekly
In contrast, Mounjaro: subcutaneous tirzepatide, dual GIP/GLP-1 receptor agonist
Tirzepatide (Mounjaro) has different pharmacology than semaglutide
Mounjaro often gives stronger weight loss effect than semaglutide injections
SURMOUNT trials support Mounjaro efficacy
Switching from tirzepatide to semaglutide involves a different pharmacological approach
Not directly interchangeable in dose or effect
Prescriber assesses whether semaglutide switch fits your situation
SLIM Films 2mg vs Rybelsus (oral semaglutide tablets)
Two non-injection semaglutide options:
SLIM Films 2mg: buccal absorption, 2mg weekly to twice weekly
In contrast, Rybelsus: oral tablet, 3-14mg daily
Rybelsus is a licensed product (Novo Nordisk) for type 2 diabetes
Rybelsus needs empty stomach and specific water volume for absorption
Rybelsus daily dosing requires consistent routine
SLIM Films weekly dosing suits different routine
Both bypass injections
Rybelsus has more clinical trial evidence
SLIM Films are compounded medicines with less specific evidence
Rybelsus isn't licensed for weight management (though prescribed off-label sometimes)
In general, Rybelsus fits daily oral tolerance; SLIM Films fit weekly maintenance preference
SLIM Films 2mg vs THIN sublingual sprays
Two Medical Mojo compounded non-injection GLP-1 options:
SLIM Films 2mg: buccal mucoadhesive film, semaglutide
In contrast, THIN sprays: sublingual spray, semaglutide or tirzepatide
Both are compounded medicines at Medical Mojo
Both bypass injection route
Films dissolve over minutes; sprays absorb quickly
Films offer sustained mucosal contact through mucoadhesion
Sprays offer faster onset from sublingual absorption
Individual patient preference varies
In general, films suit those who prefer prolonged contact and don't want spray sensation; sprays suit those preferring quick dosing
SLIM Films 2mg vs stopping GLP-1 completely
Two different post-injection strategies:
SLIM Films 2mg: continued higher-intensity GLP-1 receptor engagement
In contrast, complete discontinuation: no ongoing pharmacological support
STEP 1 extension data: patients discontinuing regained roughly two-thirds of weight lost within a year
SURMOUNT-4 data: similar pattern for tirzepatide
Complete discontinuation is genuinely more challenging for weight maintenance
Higher-intensity support may fit patients transitioning from high-dose injections
SLIM Films 2mg fit patients whose situation suggests stronger continued support helps
In general, discuss which fits your situation with prescriber
SLIM Films 2mg vs alternative approaches
Multiple options exist for this transition:
SLIM Films 2mg: higher-strength buccal semaglutide
Reduced-dose weekly injections: continued injection at lower dose
Extended interval injections: weekly injections every 2 weeks or monthly
Rybelsus oral tablets: daily oral semaglutide
THIN sublingual sprays: alternative non-injection route
SLIM Films 1mg: lower-intensity maintenance
Lifestyle-only maintenance: no pharmacological support
Each has different practical, evidence, and clinical profiles
In general, individual factors determine best fit
Who these films may suit well
This product may suit:
Adults transitioning from higher-dose GLP-1 injection therapy
Adults who found SLIM Films 1mg insufficient
Adults with significant food noise concerns
Adults needing more active appetite regulation than pure maintenance
Adults wanting stronger ongoing support without returning to injections
Adults tolerating GLP-1 gastrointestinal effects
Adults committed to ongoing lifestyle work alongside pharmacological support
Adults understanding the compounded status
Adults engaged with prescriber-led review and monitoring
Who might suit other options better
Other options may suit better for:
Adults still in active weight loss phase (continue full-dose injections)
Adults who haven't yet tried licensed weight management options
Adults for whom 1mg maintenance dose is providing enough effect (stay on 1mg)
Adults with medullary thyroid cancer or family history (contraindicated)
Adults with multiple endocrine neoplasia syndrome type 2 (contraindicated)
Adults with previous pancreatitis (contraindicated or high caution)
Adults with severe gastrointestinal disease including gastroparesis
Adults with severe hepatic impairment
Adults with severe renal impairment
Adults with active gallbladder disease
Adults with proliferative diabetic retinopathy
Adults with active eating disorders
Adults who are pregnant, planning pregnancy, or breastfeeding
Adults with active oral pathology preventing buccal absorption
Adults preferring licensed products over compounded medicines
Adults poorly tolerating GLP-1 gastrointestinal side effects
Adults who successfully maintained weight without pharmacological support previously
How SLIM Films 2mg work
Understanding the mechanism helps explain both what to expect and why higher-strength dosing suits specific clinical scenarios.
The GLP-1 mechanism
Semaglutide targets multiple pathways (same as 1mg version but stronger effect):
Binds to GLP-1 receptors in hypothalamus (appetite regulation)
Increases satiety signalling
Reduces hunger signalling
Slows gastric emptying (fullness for longer after meals)
Reduces food noise (intrusive thoughts about food)
Affects reward pathways for food (reduced food reward)
Improves insulin secretion in response to meals
Reduces inappropriate glucagon secretion
Improves glycaemic control
May have direct cardiovascular protective effects
How the buccal film works
Film placed against inner cheek mucosa
Mucoadhesive Novafilm base attaches to buccal tissue
Film begins to hydrate from saliva
Menthol enhances permeability of buccal mucosa
Semaglutide gradually released as film dissolves
Absorbed through buccal mucosa into systemic circulation
Bypasses gastric acid and digestive enzymes entirely
Bypasses first-pass hepatic metabolism
Reaches GLP-1 receptors throughout the body
Effects on appetite, gastric emptying, and glucose develop over hours to days
In short, the mechanism is identical to the 1mg version, but with double the semaglutide content per film. So the effect is stronger at similar dose frequency.
Long half-life (approximately 165 hours or around 7 days)
Steady state plasma concentrations achieved over 4-5 weeks
Weekly dosing gives smooth plasma profile
Twice-weekly dosing gives higher steady state
Buccal absorption dosing accounts for likely bioavailability differences
Individual response variability means dose frequency may be adjusted
Onset timeline
What to expect:
First week: no obvious effect for most patients; possible early GI side effects
Weeks 2-4: appetite regulation may begin to develop
Weeks 4-8: steady state plasma concentrations achieved
Beyond 8 weeks: full effect established
Individual variation is significant
Some patients notice food noise reduction earlier at 2mg than at 1mg
How to use SLIM Films 2mg
Correct technique matters for effectiveness. So take a few minutes to understand the technique before your first film.
Standard technique
Wash your hands thoroughly
Remove one film from its pouch immediately before use
Handle the film by the edges — don't touch the central area if possible
Open your mouth and dry the inner cheek surface slightly with your tongue
Place the film against the inner cheek, pressing lightly for a few seconds
The mucoadhesive base will attach to the cheek
Leave the film in place, don't chew or swallow
The film will dissolve over minutes
Avoid eating or drinking for 15-30 minutes after
Don't rinse your mouth immediately after
Practical tips
Alternate cheeks between doses to avoid local irritation
Best applied at a consistent time (allows routine)
Doesn't need to be at any particular time relative to meals
Menthol sensation confirms placement, this is normal
If film comes loose before dissolution, discuss with prescriber
Frequency
Typical starting frequency: one film per week
Can increase to two films per week if prescriber advises and initial dose is well-tolerated
Space by at least 3 days between doses
Follow prescriber's specific instructions
Higher dose means initial nausea may be more prominent — allow adaptation time
What to combine with
Comprehensive support often needs multiple elements:
Continued attention to dietary patterns
Regular physical activity
Adequate sleep
Stress management
Regular self-monitoring (weight, measurements, or wellbeing markers)
Behavioural strategies for high-risk situations
Support networks and accountability
What to avoid
Chewing or swallowing the film
Eating or drinking immediately after application
Rinsing your mouth immediately after
Combining with other GLP-1 formulations (including 1mg SLIM Films)
Using during pregnancy or breastfeeding
Using without prescriber review during treatment
If a film comes loose
If it comes off before dissolving, discuss with prescriber
Don't automatically use another one
Note timing and circumstances for pharmacist advice
Storage
Store at room temperature
Keep in original packaging
Away from direct heat and moisture
Keep out of sight and reach of children
Use by expiry date on packaging
Store separately from any 1mg SLIM Films you may have to prevent dose confusion
Warnings and precautions
Semaglutide has important safety considerations. Side effects and warnings apply particularly at the higher 2mg dose.
Don't use SLIM Films 2mg if you
Have personal or family history of medullary thyroid carcinoma
Have multiple endocrine neoplasia syndrome type 2 (MEN2)
Have had pancreatitis
Have severe gastrointestinal disease including gastroparesis
Have severe hepatic impairment
Have severe renal impairment (end-stage)
Are pregnant or planning pregnancy
Are breastfeeding
Have known allergy to semaglutide or any excipient
Have active oral pathology that would prevent absorption
Have active eating disorder
The higher-dose consideration
Specific to 2mg use:
Nausea and GI effects may be more prominent than at 1mg
Adjustment period may be more noticeable
Some patients need to reduce back to 1mg if not tolerated
Starting once weekly then increasing frequency helps adaptation
Prescriber discusses tolerance strategy
The pancreatitis warning
Rare but serious:
GLP-1 agonists have been associated with pancreatitis in post-marketing data
Absolute risk is low but real
Previous pancreatitis is a contraindication
Symptoms: severe upper abdominal pain radiating to back, nausea, vomiting
Stop treatment and seek urgent medical assessment if pancreatitis suspected
The thyroid warning
Contraindication basis:
Rodent studies showed thyroid C-cell tumours with GLP-1 agonists
Human relevance unclear but precautionary contraindication in medullary thyroid cancer and MEN2
Family history of medullary thyroid cancer is a contraindication
New neck lumps or thyroid symptoms during treatment need assessment
The gallbladder warning
Increased risk documented:
GLP-1 agonists increase risk of gallstone-related events
Weight loss itself also increases gallstone risk
Symptoms: right upper abdominal pain, particularly after fatty meals
Active gallbladder disease is a relative contraindication
The diabetic retinopathy warning
Relevant for diabetics:
Rapid glycaemic changes can worsen diabetic retinopathy
Proliferative retinopathy is a relative contraindication
Retinal review recommended before starting in diabetics with retinopathy
The eating disorder consideration
Important safeguard:
Active eating disorders (anorexia, bulimia) are contraindications
Past eating disorders warrant specialist input before GLP-1 use
Body image dysmorphia warrants careful assessment
Prescriber screens for eating disorder markers
Use with care if you
Have mild-to-moderate renal impairment
Have mild-to-moderate hepatic impairment
Have gastroparesis or slowed gastric emptying
Have gastro-oesophageal reflux disease
Have type 1 diabetes (semaglutide not licensed for this)
Are on insulin or sulphonylurea (hypoglycaemia risk)
Are over 75 years old (limited data in very elderly)
Have had bariatric surgery (specialist input recommended)
Poorly tolerated GI effects at 1mg (2mg may worsen)
Pregnancy and breastfeeding
Not for use during pregnancy or planning pregnancy
Not for use during breastfeeding
Stop treatment at least 2 months before planned conception
Effective contraception during use in women of childbearing age
Driving and machinery
Generally doesn't affect driving:
SLIM Films don't typically affect driving
Hypoglycaemia risk if used alongside diabetic medications
Nausea during initial dosing may affect concentration, particularly at 2mg
When to seek urgent medical help
Severe upper abdominal pain (possible pancreatitis)
Right upper abdominal pain (possible gallstones)
Signs of severe allergic reaction (facial swelling, breathing difficulty)
New neck lumps or persistent hoarseness
Persistent severe vomiting
Signs of dehydration
Vision changes (in diabetics)
Side effects
Semaglutide has a well-characterised side effect profile from licensed injectable and oral formulations. Side effects may be more prominent at 2mg than at 1mg.
Common side effects
Nausea (especially initially, often more prominent at 2mg)
Vomiting
Diarrhoea
Constipation
Abdominal pain
Dyspepsia (indigestion)
Reduced appetite
Fatigue
Headache
Local mucosal irritation (buccal-specific)
Menthol taste sensation
Less common side effects
Hypoglycaemia (if used alongside diabetic medications)
Belching
Flatulence
Bloating
Gastro-oesophageal reflux
Local reactions at buccal site
Altered taste
Dizziness
Rare side effects
Acute pancreatitis
Gallbladder events (gallstones, cholecystitis)
Acute kidney injury (associated with dehydration from vomiting/diarrhoea)
Diabetic retinopathy worsening
Allergic reactions
Elevated pancreatic enzymes
Very rare side effects
Severe allergic reactions (anaphylaxis)
Angioedema
The GI symptoms question at 2mg
More prominent at higher dose:
Nausea and other GI symptoms are the most common side effects, more so at 2mg than 1mg
Typically improve over weeks as the body adjusts
Small frequent meals help
Avoiding high-fat meals helps
Adequate hydration important
If severe or persistent, consider stepping back to 1mg
Discuss with prescriber if tolerance is an issue
Stop and seek urgent medical help if
Severe upper abdominal pain
Signs of severe allergic reaction
Persistent severe vomiting causing dehydration
Vision changes
New neck lumps
Yellow Card reporting
If you experience any side effects, you can report them via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Reporting side effects helps improve safety information for all patients.
Drug interactions
Semaglutide has several important interactions to consider.
Interactions requiring care
Insulin — hypoglycaemia risk, may need insulin dose reduction
Alcohol can worsen hypoglycaemia risk in diabetics
May increase GI side effects (particularly relevant at 2mg dose)
Also affects appetite regulation
Moderation advised
Frequently asked questions
How is 2mg different from 1mg?
Same delivery, double the semaglutide:
2mg contains double the semaglutide per film
Provides stronger appetite regulation
May reduce food noise more effectively
Higher rates of GI side effects (particularly nausea)
Same buccal delivery format and dosing frequency
Choose based on individual clinical need
Should I start on 1mg or 2mg?
Depends on your situation:
Coming off maintenance-dose injections: usually 1mg is sensible starting point
Coming off high-dose injections (Wegovy 2.4mg): 2mg may fit better initially
Never used GLP-1s before: injections usually fit better for active weight loss
Tried 1mg and found insufficient: 2mg may help
Prescriber assessment guides the decision
Can I switch between 1mg and 2mg?
Yes, with prescriber guidance:
Step up from 1mg to 2mg if effect isn't enough
Step down from 2mg to 1mg if side effects are troublesome
Don't combine 1mg and 2mg films — choose one strength
Prescriber discusses timing of dose changes
Will 2mg cause more nausea?
Often yes, particularly initially:
Higher dose means more prominent GI effects typically
Nausea usually improves over weeks as body adjusts
Small frequent meals help
Avoiding high-fat meals helps
If severe or persistent, consider stepping back to 1mg
Can I use 2mg for active weight loss?
Not the typical positioning:
2mg SLIM Films aren't equivalent to full 2.4mg Wegovy injections
For active weight loss, injection therapy usually fits better
2mg positioning is between maintenance and active weight loss
Some patients may see modest additional weight loss on 2mg
Realistic expectations matter
How fast do they work?
Gradual effect:
Steady state builds over 4-5 weeks
Some patients notice food noise reduction earlier than at 1mg
Full effect typically 6-8 weeks
Not for acute effect
Can I combine with injections?
No, don't combine:
Don't combine SLIM Films with any other GLP-1 formulation
This would cause excessive dosing
Choose one approach at a time
Can I use in pregnancy?
No:
Semaglutide contraindicated in pregnancy
Stop treatment at least 2 months before planned conception
Effective contraception during use
Contact prescriber if pregnancy occurs during treatment
What if 2mg is too strong?
Options include:
Reduce frequency (once weekly instead of twice weekly)
Step back to 1mg SLIM Films
Alternative maintenance approach
Discuss with prescriber
What if 2mg isn't enough?
Consider alternatives:
May indicate injection therapy fits better
Buccal absorption has natural upper limits
Comprehensive lifestyle review may help
Discuss with prescriber
How long can I stay on 2mg?
Depends on individual factors:
Some patients use short-term during transition off high-dose injections then step to 1mg
Some patients use longer-term for ongoing higher-intensity support
Regular prescriber review essential
Not intended as permanent daily use replacement for lifestyle work
What if I get severe abdominal pain?
Stop and seek assessment:
Severe upper abdominal pain radiating to the back can indicate pancreatitis
Right upper abdominal pain can indicate gallstones
Both need urgent medical assessment
Stop SLIM Films pending assessment
How should I store them?
Room temperature
In original packaging
Away from direct heat and moisture
Keep out of reach of children
Use by expiry date
Store separately from 1mg SLIM Films to prevent dose confusion
Is my packaging discreet?
Plain packaging with no mention of contents
Suitable for delivery to home or workplace
How do I order from Medical Mojo?
Complete the weight management consultation on medicalmojo.co.uk. Our prescriber will review your treatment history and current situation, then arrange compounding by APC Labs if suitable. Your order goes out in plain, discreet packaging with support available throughout your treatment.
Disclaimer
This page is for information only and isn't a substitute for personal medical advice.
SLIM Films are an unlicensed compounded medicine containing semaglutide, made available under the compounding pathway based on individual prescriber judgement.
Semaglutide is contraindicated in medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, pregnancy, and breastfeeding.
Prescriber assessment before use is essential.
The 2mg dose is higher than the 1mg maintenance strength and may cause more prominent GI side effects.
Signs of pancreatitis (severe upper abdominal pain radiating to back with nausea and vomiting) need urgent medical assessment.
Signs of severe allergic reaction (facial swelling, breathing difficulty, widespread rash) need immediate medical attention (999).
SLIM Films 2mg are positioned for higher-intensity ongoing GLP-1 support, not for active weight loss.
Licensed injectable products typically fit active treatment phase better. This product should be used alongside comprehensive lifestyle approaches to weight management.
